Technology News and Research

RSS

Georgia Institute of Technology receives EPA safe drinking water research grant

The U.S. Environmental Protection Agency announced the award of a $600,000 research grant to Georgia Tech to improve the detection of known and emerging drinking water contaminants; including the harmful substances produced by blue-green algae in algal blooms and noroviruses.

4 Sep 2008

African countries commit to new meningitis vaccine

Health ministers from countries of the African meningitis belt today committed themselves to introduce a highly promising candidate meningitis vaccine. The vaccine is designed to prevent periodic epidemics of the deadly disease in these countries.

4 Sep 2008

Nanotherapeutics files INDA for NanoDOX hydrogel to treat type of diabetic ulcers

Nanotherapeutics announced today that it has submitted its first Investigational New Drug (IND) application to the FDA for a phase IIa clinical study for its product NanoDOX Hydrogel, a topical doxycycline hydrogel for chronic wounds.

4 Sep 2008

Invitrogen launches patent licensing program for random prime amplification of nucleic acids

Invitrogen Corporation today announced that it has signed non-exclusive agreements with New England Biolabs, Inc., QIAGEN GmbH, and Kirkegaard & Perry Laboratories, Inc. (KPL), whereby the companies have licensed Invitrogen's patented technology covering the random prime amplification of nucleic acids. Financial terms of the agreements were not disclosed.

4 Sep 2008

Africa can successfully fight malaria with increased resources, commitment, WHO Director General says

Africa can achieve success in combating malaria and other diseases with sufficient resources and increased commitment from African leaders, World Health Organization Director-General Margaret Chan said Monday at the opening of the 58th session of WHO's Regional Committee for Africa in Yaounde, Cameroon, the Cameroon Tribune reports.

4 Sep 2008

President Bush signs law to ensure health benefits for 'sole survivor' veterans

President Bush on Friday signed into law legislation (HR 5825, S 2874) that will guarantee health benefits for "sole survivor" veterans who receive honorable discharges, the Los Angeles Times reports.

4 Sep 2008

Anadis to commercialise "BioGard" adjunctive therapy for HIV/AIDS

Anadis announced today its commercialization of a new product, BioGard, intended to maintain gastrointestinal and immune system health. The specific formulation may be of particular clinical benefit in persons undergoing antiretroviral therapy for HIV/AIDS.

4 Sep 2008

Clinical trial advances cystic fibrosis therapy

Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different doses of the new drug.

4 Sep 2008

Panacea Pharmaceuticals issued U.S. patent for anti-HAAH antibodies

Panacea Pharmaceuticals, Inc. has announced the issuance of U.S. Patent Number 7,413,737 covering antibodies against human aspartyl (asparaginyl) beta-hydroxylase (HAAH), a proprietary human cancer biomarker and therapeutic target.

3 Sep 2008

Single embryo advice to IVF clinics will reduce the number of multiple births

Experts in the UK are advising that wherever possible, only one embryo per IVF cycle should be transferred in order to cut the rate of multiple births.

3 Sep 2008

New software promises to reduce bottlenecks in emergency departments

Australian researchers have developed a computer program which is able to accurately predict how many patients can be expected to turn up at hospital emergency departments and their expected medical needs and also promises to reduce bottlenecks in emergency departments.

3 Sep 2008

Monitoring immune responses in disease

A recent study published in Clinical Immunology, the official journal of the Clinical Immunology Society (CIS), describes a new method enabling the detection of multiple parameters of single human cells.

3 Sep 2008

Anadis Ltd's clinical trial against mucositis approved in Israel

Anadis Ltd., an Australian biopharmaceutical company specializing in oral immunotherapy using naturally derived antibodies and other proteins is announcing the clinical protocol for its Cancer-related Mucositis Program was cleared by the Tel Aviv Souraski Medical Center's Institutional Review Board (IRB) and by the Israeli Ministry of Health (MOH).

3 Sep 2008

CDC report on new HIV infections in U.S. did not include data from Puerto Rico; omission has widespread consequences, advocates say

A CDC report released last month about new annual HIV infections in the U.S. did not include data from Puerto Rico, an omission that Hispanic HIV/AIDS advocates say could have widespread consequences nationwide, the Orlando Sentinel reports.

2 Sep 2008

Spinifex secures major investment to develop pain drug

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured venture capital investment of A$12 million from GBS Venture Partners Limited, Brandon Capital Partners and Uniseed to fund the development of its pain management drug, EMA401.

2 Sep 2008

Discovery of novel candidate gene for inflammatory bowel diseases

A study of Crohn's disease and ulcerative colitis in children has identified a gene that influences whether children get these diseases early in life, and points to a potential new target for treatment.

2 Sep 2008

New stem cell tools to aid drug development

Scientists have designed, developed and tested new molecular tools for stem cell research to direct the formation of certain tissue types for use in drug development programmes.

2 Sep 2008

First patient enrolled in study evaluating S.M.A.R.T. Nitinol self-expandable stent

Cordis Corporation has announced the first patient enrollment in the STROLL trial, which will evaluate the safety and efficacy of the S.M.A.R.T. Nitinol Self-Expandable Stent System in treating patients with obstructive superficial femoral artery (SFA) disease, also known as SFA atherosclerosis.

2 Sep 2008

The role played by drug-eluting stents in reducing acute myocardial infarction

The safety debate about drug-eluting stents (DES) is still ongoing. In these times of uncertainty about DES safety, the study has shown that DES markedly improve long-term survival compared to modern bare-metal stents (BMS) implantation in patients with acute ST-segment elevation myocardial infarction (STEMI). In our four year investigation, DES demonstrated a significant reduction of mortality in this sick patient subset.

2 Sep 2008

Fibrin-derived peptide FX06 reduces cardiac reperfusion injury

Data presented today at the European Society of Cardiology Congress demonstrates the effectiveness of a peptide called FX06 in preventing cardiac damage resulting from treatment following a heart attack.

2 Sep 2008